Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 known ✓ | P05230 | 1/20 | 0.45 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | ATIC | P31939 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.44 |
| ▸ | DUSP5 | Q16690 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 2/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | CLTC | Q00610 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28471752 | 0.96 | HSD17B10 (0.51) | HSD17B10CYP2C9CYP2C19ATICALDH1A1 | |
| SCHEMBL4113857 | 0.86 | ALDH1A1 (0.47) | HSD17B10CYP2C9CYP2C19ATICALDH1A1 | |
| SCHEMBL1807955 | 0.84 | LMNA (0.58) | HSD17B10CYP2C9CYP2C19ATICALDH1A1 | |
| SCHEMBL29518641 | 0.82 | ALDH1A1 (0.62) | HSD17B10CYP2C9CYP2C19ATICALDH1A1 | |
| SCHEMBL29941351 | 0.82 | ALDH1A1 (0.62) | HSD17B10CYP2C9CYP2C19ATICALDH1A1 | |
| SCHEMBL157169 | 0.82 | ALDH1A1 (0.62) | HSD17B10CYP2C9CYP2C19ATICALDH1A1 | |
| SCHEMBL4311014 | 0.82 | HSD17B10 (0.51) | HSD17B10CYP2C9CYP2C19ATICALDH1A1 | |
| SCHEMBL28474739 | 0.82 | ALDH1A1 (0.47) | HSD17B10CYP2C9CYP2C19ATICALDH1A1 | |
| SCHEMBL11439997 | 0.81 | ALDH1A1 (0.47) | HSD17B10CYP2C9CYP2C19ALDH1A1SLC7A11 | |
| SCHEMBL30495977 | 0.81 | FGF1 (0.47) | FGF1DUSP5THRBCASP6CLTC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116273159-B | Sulfonated immobilized binary catalyst, preparation method and application thereof | 中国人民解放军军事科学院系统工程研究院 | 2023-11-17 | — | — | CN | claimed |
| CN-116273159-A | Sulfonated immobilized binary catalyst, preparation method and application thereof | 中国人民解放军军事科学院系统工程研究院 | 2023-06-23 | — | — | CN | claimed |
| US-20090306132-A1 | USE OF DERIVATIVES OF NAPHTHALENESULPHONIC OR QUINOLINESULPHONIC ACID IN THE TREATMENT OF VASOPROLIFERATIVE OCULAR DISEASES | ITALFARMACO, S.A. (ES) | 2009-12-10 | — | — | US | claimed |
| US-20090076140-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES | ITALFARMACO, S. A. (ES) | 2009-03-19 | — | — | US | claimed |
| EP-1994929-A1 | USE OF DERIVATIVES OF NAPHTHALENESULPHONIC OR QUINOLINESULPHONIC ACID IN THE TREATMENT OF VASOPROLIFERATIVE OCULAR DISEASES | ITALFARMACO, S.A. (ES) | 2008-11-26 | — | — | EP | claimed |
| US-20060160849-A1 | Pharmaceutical compositions containing sulphonic acid derivatives | ITALFARMACO, S.A. (ES) | 2006-07-20 | — | — | US | claimed |
| EP-1602644-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES | Italfarmaco, S.A. (ES) | 2005-12-07 | — | — | EP | claimed |
| CN-116273159-B | Sulfonated immobilized binary catalyst, preparation method and application thereof | 中国人民解放军军事科学院系统工程研究院 | 2023-11-17 | — | — | CN | disclosed |
| CN-116273159-A | Sulfonated immobilized binary catalyst, preparation method and application thereof | 中国人民解放军军事科学院系统工程研究院 | 2023-06-23 | — | — | CN | disclosed |
| US-20160369237-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECH INC (US) | 2016-12-22 | — | — | US | disclosed |
| EP-1754756-B1 | Carbon material | ORION ENG CARBONS GMBH (DE) | 2016-12-07 | — | — | EP | disclosed |
| CN-1908077-B | Carbon material | DEGUSSA | 2012-08-22 | — | — | CN | disclosed |
| CN-101240119-B | Carbon black reacted with diazonium salts and products | CABOT CORP | 2011-05-11 | — | — | CN | disclosed |
| CN-1321708-A | Carbon black reacted with diazols, and products | CABOT CORP (US) | 2001-11-14 | — | — | CN | disclosed |
| CN-1175270-A | Carbon black reacted with diazonium salts and products | CABOT CORP (US) | 1998-03-04 | — | — | CN | disclosed |
| EP-0793653-A1 | CERTAIN 4-AMINOMETHYL-2-SUBSTITUTED IMIDAZOLE DERIVATIVES AND 2-AMINOMETHYL-4-SUBSTITUTED IMIDAZOLE DERIVATIVES; NEW CLASSES OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1997-09-10 | — | — | EP | disclosed |
| EP-0558258-B1 | N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists | SQUIBB & SONS INC (US) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996016040-A1 | CERTAIN 4-AMINOMETHYL-2-SUBSTITUTED IMIDAZOLE DERIVATIVES AND 2-AMINOMETHYL-4-SUBSTITUTED IMIDAZOLE DERIVATIVES; NEW CLASSES OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1996-05-30 | — | — | WO | disclosed |
| US-5378715-A | Sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1995-01-03 | — | — | US | disclosed |
| EP-0558258-A1 | N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306132-A1 | USE OF DERIVATIVES OF NAPHTHALENESULPHONIC OR QUINOLINESULPHONIC ACID IN THE TREATMENT OF VASOPROLIFERATIVE OCULAR DISEASES | NQO2, SQLE, SQOR | FGF1 693/4885THRB 4784/4885HSD17B10 1854/4885 |
| US-20090076140-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING SULPHONIC ACID DERIVATIVES | SUCNR1, NR1H4, CYP2B6 | FGF1 1378/4885THRB 2224/4885HSD17B10 436/4885 |
| US-20060160849-A1 | Pharmaceutical compositions containing sulphonic acid derivatives | SUCNR1, NR1H4, CYP2B6 | FGF1 1320/4885THRB 2260/4885HSD17B10 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.